Median Technologies (XPAR:ALMDT) GF Value : €10.61 (As of May. 25, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Median Technologies GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-25), Median Technologies's share price is €3.70. Median Technologies's GF Value is €10.61. Therefore, Median Technologies's Price-to-GF-Value for today is 0.35.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Median Technologies is Possible Value Trap, Think Twice.

Median Technologies (XPAR:ALMDT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Median Technologies's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	3.70	/	10.61
	=	0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Median Technologies GF Value Related Terms

Thank you for viewing the detailed overview of Median Technologies's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Median Technologies (XPAR:ALMDT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

4ZG:Germany

Address

1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560

Website

https://www.mediantechnologies.com

Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies (XPAR:ALMDT) Headlines

No Headlines